Atlas Venture Life Science Advisors LLC Decreases Stake in Sionna Therapeutics, Inc. $SION

Atlas Venture Life Science Advisors LLC trimmed its holdings in shares of Sionna Therapeutics, Inc. (NASDAQ:SION) by 17.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,995,602 shares of the company’s stock after selling 619,925 shares during the quarter. Sionna Therapeutics accounts for about 14.2% of Atlas Venture Life Science Advisors LLC’s portfolio, making the stock its 3rd largest position. Atlas Venture Life Science Advisors LLC owned 0.07% of Sionna Therapeutics worth $123,239,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. GF Fund Management CO. LTD. bought a new stake in Sionna Therapeutics during the 4th quarter worth approximately $36,000. Russell Investments Group Ltd. bought a new stake in Sionna Therapeutics during the 3rd quarter worth approximately $30,000. BNP Paribas Financial Markets bought a new stake in Sionna Therapeutics during the 2nd quarter worth approximately $31,000. Mirae Asset Global Investments Co. Ltd. bought a new stake in Sionna Therapeutics during the 4th quarter worth approximately $89,000. Finally, AlphaCentric Advisors LLC bought a new stake in Sionna Therapeutics during the 4th quarter worth approximately $112,000.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the stock. JonesTrading boosted their target price on shares of Sionna Therapeutics from $52.00 to $63.00 and gave the stock a “buy” rating in a report on Tuesday, April 28th. BTIG Research reissued a “buy” rating and set a $58.00 target price on shares of Sionna Therapeutics in a report on Wednesday, May 13th. Stifel Nicolaus upped their target price on Sionna Therapeutics from $44.00 to $55.00 and gave the company a “buy” rating in a report on Monday, May 18th. Lifesci Capital upgraded Sionna Therapeutics to a “strong-buy” rating in a report on Wednesday, February 25th. Finally, Wall Street Zen cut Sionna Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Three investment analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $53.22.

Sionna Therapeutics Price Performance

Shares of SION stock opened at $35.92 on Friday. Sionna Therapeutics, Inc. has a one year low of $13.51 and a one year high of $48.44. The business’s 50 day simple moving average is $40.09 and its 200 day simple moving average is $39.70. The stock has a market capitalization of $1.62 billion, a PE ratio of -18.61 and a beta of 1.30.

Sionna Therapeutics (NASDAQ:SION) last announced its earnings results on Tuesday, May 12th. The company reported ($0.60) EPS for the quarter, missing the consensus estimate of ($0.52) by ($0.08). As a group, research analysts expect that Sionna Therapeutics, Inc. will post -2.57 earnings per share for the current year.

Insider Buying and Selling

In other Sionna Therapeutics news, Director Orbimed Advisors Llc sold 235,863 shares of the stock in a transaction that occurred on Wednesday, April 15th. The stock was sold at an average price of $44.64, for a total transaction of $10,528,924.32. Following the transaction, the director directly owned 3,247,025 shares in the company, valued at approximately $144,947,196. This represents a 6.77% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Peter A. Thompson sold 235,863 shares of the stock in a transaction that occurred on Wednesday, April 15th. The stock was sold at an average price of $44.64, for a total value of $10,528,924.32. Following the transaction, the director owned 3,247,025 shares in the company, valued at $144,947,196. The trade was a 6.77% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 1,717,962 shares of company stock worth $77,571,889 over the last 90 days. Company insiders own 5.10% of the company’s stock.

Sionna Therapeutics Profile

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.